Skip to main content
OpenTrials
Completed

NCT Number: NCT06629441

Effectiveness and Safety of Probiotics in Relieving Anxiety and Depression

To evaluate the effectiveness and safety of probiotics in relieving anxiety and depression in adults, in comparison with placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The 1st Affiliated Hospital of He'nan University of Science and Technology

Luoyang, Henan, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary, Written, and Signed Informed Consent: Agreeing to participate in the study.
  • Ability to Complete the Study According to Protocol: Able to meet the requirements of the study protocol.
  • Age: 18-65 years old.
  • Depression and Anxiety Scores:
  • Hamilton Depression Rating Scale (HAMD-17) score of 20 or higher, or
  • Hamilton Anxiety Rating Scale (HAMA) score of 14 or higher.
  • No History of Certain Conditions: No history of heart, liver, kidney, nervous system, psychiatric disorders, or metabolic abnormalities.

Exclusion criteria

  • Past Diagnosis of Certain Conditions: Individuals with a history of other clearly diagnosed psychiatric disorders, intellectual disabilities, consciousness disorders, complete aphasia, bipolar disorder, treatment-resistant depression, or suicidal thoughts.
  • Pregnant or Breastfeeding Women: Individuals who are pregnant or breastfeeding.
  • Use of Certain Medications: Individuals who have used anti-anxiety, anti-depressant medications, or mood stabilizers within the past month.
  • Allergy History: Individuals with allergic constitutions or a history of drug allergies, or those with severe systemic diseases.
  • Substance Abuse History: Individuals with a history of alcohol or psychoactive substance abuse within the past 3 months.
  • Impact of Medications on Gut Microbiota: Individuals who have used medications affecting gut microbiota (including antibiotics, probiotics, mucosal protectors, traditional Chinese medicine, etc.) continuously for more than 1 week in the month prior to screening.
  • Discontinuation or Addition of Medications: Individuals who have stopped taking the study medication or started taking other medications, making it difficult to assess efficacy or with incomplete data.
  • Use of Similar Products: Individuals who have taken items similar to the study product in the short term, affecting the evaluation of results.
  • Inability to Participate: Research participants who cannot participate in the study due to personal reasons.
  • Other Exclusions: Participants deemed unsuitable for the study by the researchers.

Treatment and study plan

Probiotic group

Dietary Supplement

taking 10 billion CFU probiotic one sachet one time, lasting 56 days.

Placebo Group

Dietary Supplement

taking maltodaxtrin one sachet one time, lasting 56 days.

Primary outcomes

  1. Change in Hamilton Depression Rating Scale (HAMD-17) total score from baseline to Week 8

    Time frame: Baseline and Week 8

    Clinician-rated HAMD-17; higher scores indicate more severe depressive symptoms. Negative change denotes improvement.

Sponsors and collaborators

Lead sponsor

Wecare Probiotics Co., Ltd.

Industry

Registry information

Official study title

Effectiveness and Safety of Probiotics, BC99 in Relieving Anxiety and Depression in Adults

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Oct 8, 2024
Registry last updated
Aug 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.